Hans Chung

Biography

Dr. Chung's clinical focus is genitourinary and gastrointestinal malignancies. His specialized skills include high-dose rate (HDR) and low-dose rate prostate brachytherapy and stereotactic body radiotherapy for liver cancers. His research interests include leading clinical studies in salvage HDR brachytherapy and stereotactic body radiotherapy for liver metastases. Dr. Chung is the co-chair of RTOG-0924, a North American cooperative phase 3 trial studying the impact of whole pelvic radiotherapy in patients with unfavourable intermediate-risk and favourable high-risk prostate cancer in the setting of dose-escalated radiotherapy. Dr. Chung is the principal investigator of a single-institution pilot study on focal and whole gland salvage HDR brachytherapy for local recurrence of prostate cancer after external beam radiotherapy. This study is open for accrual. In partnership with Dr. Greg Czarnota and his team, Dr. Chung is studying the use of quantitative ultrasound to identify prostate cancer. He is also studying the effects of definitive radiotherapy for prostate cancer as measured by ultrasound spectroscopy and elastography. In collaboration with Dr. Y. Ko, Dr. Chung is the co-principal investigator in a single-institution pilot study of the imaging effects of bevacizumab as a radiosensitizer with stereotactic body radiotherapy for liver metastases secondary to colorectal cancer. Novel imaging techniques such as dynamic contrast-enhanced computed tomography, contrast-enhanced ultrasound and quantitative ultrasound are being used.

Research Interest

Prostate brachytherapy, Stereotactic body radiotherapy for oligometastases and liver metastases.